Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 266-272

  Swart, Andreas ^a   Burlingame, Rufus W ^b   Gürtler, Irmgard ^a   Mahler, Michael ^b  

^a Center for Rheumatic Diseases   (Germany)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Autoantibodies; CCP; Citrullinated cyclic peptide; RA; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE 2; CYCLIC CITRULLINATED PEPTIDE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE 3; CYCLIC CITRULLINATED PEPTIDE 3 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FILAGGRIN; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FEMALE; FIBROMYALGIA; HUMAN; IMMUNOASSAY; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SPINE DISEASE; BLOOD; IMMUNOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SENSITIVITY AND SPECIFICITY;

EID: 84868236032     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.09.015     Document Type: Article

References (39)

1. van Venrooij, W.J., van Beers, J.J., Pruijn, G.J., Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 7 (2011), 391–398.
2. Wiik, A.S., van Venrooij, W.J., Pruijn, G.J., All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 10 (2010), 90–93.
3. Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev in press, http://dx.doi.org/10.1016/j.autrev.2012.05.007.
4. Schellekens, G.A., de Jong, B.A., van den Hoogen, F.H., van de Putte, L.B., van Venrooij, W.J., Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101 (1998), 273–281.
5. Aletaha, D., Neogi, T., Silman, A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 (2010), 2569–2581.
6. Aletaha, D., Neogi, T., Silman, A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
7. Kessenbrock, K., Raijmakers, R., Fritzler, M.J., Mahler, M., Synthetic peptides: the future of patient management in systemic rheumatic diseases?. Curr Med Chem 14 (2007), 2831–2838.
8. Levesque, M.C., Zhou, Z., Moreland, L.W., Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum 60 (2009), 2211–2215.
9. Vander, C.B., Nogueira, L., Van, P.J., et al. Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 67 (2008), 542–546.
10. Bizzaro, N., Tonutti, E., Tozzoli, R., Villalta, D., Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 53 (2007), 1527–1533.
11. Santiago, M., Baron, M., Miyachi, K., et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 27 (2008), 77–83.
12. Correia, M.L., Carvalho, S., Fortuna, J., Pereira, M.H., Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 34 (2008), 21–25.
13. van der Linden, M.P., van der Woude, D., Ioan-Facsinay, A., et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60 (2009), 2232–2241.
14. Jaskowski, T.D., Hill, H.R., Russo, K.L., Lakos, G., Szekanecz, Z., Teodorescu, M., Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol 37 (2010), 1582–1588.
15. van Venrooij, W.J., Zendman, A.J., Pruijn, G.J., Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6 (2006), 37–41.
16. Pruijn, G.J., Wiik, A., van Venrooij, W.J., The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther, 12, 2010, 203.
17. Bossuyt, X., Coenen, D., Fieuws, S., Verschueren, P., Westhovens, R., Blanckaert, N., Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 68 (2009), 287–289.
18. Pratesi, F., Tommasi, C., Anzilotti, C., et al. Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol 164 (2011), 337–345.
19. Bartoloni, E., Alunno, A., Bistoni, O., et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 11 (2012), 815–820.
20. Dejaco, C., Klotz, W., Larcher, H., Duftner, C., Schirmer, M., Herold, M., Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther, 8, 2006, R119.
21. Soos, L., Szekanecz, Z., Szabo, Z., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34 (2007), 1658–1663.
22. Damjanovska, L., Thabet, M.M., Levarth, E.W., et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69 (2010), 730–732.
23. Nell, V.P., Machold, K.P., Stamm, T.A., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64 (2005), 1731–1736.
24. Chandra, P.E., Sokolove, J., Hipp, B.G., et al. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther, 13, 2011, R102.
25. Shoda, H., Fujio, K., Shibuya, M., et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther, 13, 2011, R191.
26. Arnett, F.C., Edworthy, S.M., Bloch, D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988), 315–324.
27. Fijorek, K., Fijorek, D., Wisniowska, B., Polak, S., BDTcomparator: a program for comparing binary classifiers. Bioinformatics 27 (2011), 3439–3440.
28. Nofuentes, J.A., Del Castillo, J.D., Comparison of the likelihood ratios of two binary diagnostic tests in paired designs. Stat Med 26 (2007), 4179–4201.
29. Silveira, I.G., Burlingame, R.W., von Muhlen, C.A., Bender, A.L., Staub, H.L., Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 26 (2007), 1883–1889.
30. Rottmann, M., Anti-CCP: challenges in quantifying auto-antibodies and creating international reference materials. Scand J Clin Lab Invest Suppl 242 (2010), 44–45.
31. Willemze, A., Bohringer, S., Knevel, R., et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 71 (2012), 268–274.
32. Sokolove, J., Bromberg, R., Deane, K.D., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One, 7, 2012, e35296.
33. Elrefaei, M., Boose, K., McGee, M., et al. Second Generation Automated Anti-CCP Test Better Predicts the Clinical Diagnosis of Rheumatoid Arthritis. J Clin Immunol 32 (2012), 131–137.
34. Kokkonen, H., Mullazehi, M., Berglin, E., et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther, 13, 2011, R13.
35. Cader, M.Z., Filer, A., Hazlehurst, J., de Pablo, P., Buckley, C.D., Raza, K., Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 70 (2011), 949–955.
36. Fautrel, B., Combe, B., Rincheval, N., Dougados, M., Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. Ann Rheum Dis 71 (2012), 386–389.
37. Aletaha, D., Eberl, G., Nell, V.P., Machold, K.P., Smolen, J.S., Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 63 (2004), 1269–1275.
38. Somers, K., Geusens, P., Elewaut, D., et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun 36 (2011), 33–46.
39. Shi, J., Knevel, R., Suwannalai, P., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 108 (2011), 17372–17377.